Co-administration of African potato and cisplatin for treating breast and prostate cancers using a Pheroid® delivery system
Date
2019Author
Lambert, Maarten
Okem, Ambrose
Hayeshi, Rose
De Graaf, Inge
Metadata
Show full item recordAbstract
The cancer burden is increasing worldwide and is expected tobecome the most important barrier to increasing life expectancy 21stcentury. Low- and middle-income countries are expected to showthe biggest increase in incidence. Cisplatin is a frequently usedchemotherapy, however, challenges like drug resistance and sideeffects have yet to be overcome. A promising solution to thisproblem is the co- administration of cisplatin with other compounds.Many cancer patients in sub-Saharan countries co-administer herbaland prescription drugs. African potato (AP) is a popular choice for itsnegligible side effects and immune-boosting properties. One problemassociated with orally administered drug is poor bioavailability. ThePheroid® delivery system has shown to improve drug bioavailabilityand efficacy. No studies have been done on the interaction between AP and cisplatin, hence, this study aims to formulate a combinationof AP and cisplatin in Pheroids® and evaluate its anticancerproperties. Cytotoxicity of AP and cisplatin will be testedin vitroagainst breast (MCF-7) and prostate (PC-3) cancer cell lines todetermine the combination (CI) and dose reduction index of AP withcisplatin. Pheroids® will be examined for their optimal formulation.Anticancer activity of Pheroid® formulations will be tested throughvarious assays. For the pharmacokinetic study, Sprague- Dawley ratswill be used due to the volume of the blood samples required. Ratswill be administered with cisplatin, unformulated AP-cisplatin orPheroid® formulated AP-cisplatin (N= 10). For the efficacy study,nude mice that will be used as the models have already beenestablished. Animals will be implanted with either PC-3 or MCF-7cells. Once tumor volume has reached≥150 mm3 they will be treatedwith cisplatin, unformulated AP-cisplatin, Pheroid® formulated AP-cisplatin or empty Pheroids® (N= 10). AP and cisplatin have asimilar mode of action, hence synergistic activity whenco-administered is expected. As a result, lower concentrations ofcisplatin are expected to yield potent activity compared to individualadministration, for both Pheroid® formulations and free drugformulations
URI
http://hdl.handle.net/10394/33318https://www.sciencedirect.com/science/article/pii/S1056871919303260
https://doi.org/10.1016/j.vascn.2019.106608